

## NMD OUTCOME MEASURES

**1. Diagnostic Mammography Positive Predictive Value 2 (PPV2 - Biopsy Recommended)** – proportion of patients recommended for biopsy who are subsequently diagnosed with breast cancer.

**2. Screening Mammography Positive Predictive Value 2 (PPV2 – Biopsy Recommended)** – proportion of patients recommended for biopsy who are subsequently diagnosed with breast cancer.

**3. Cancer Detection Rate (CDR)** – cancers correctly detected at mammography per 1,000 patients screened.

**4. Abnormal Interpretation Rate (Recall Rate)** – proportion of screening mammogram interpretations that lead to additional imaging or biopsy.

### **Outcome Measure 1: Diagnostic Mammography Positive Predictive Value 2**

Data Elements	Clinical Performance Measure
Date of examination	<p><b>Numerator:</b> Number of diagnostic mammograms with a BI-RADS® assessment category of 0, 4 or 5 that had a tissue diagnosis of cancer within 12 months.</p> <p><b>Denominator:</b> Number of diagnostic exams with a BI-RADS® assessment category of 4 or 5</p> <p><b>Numerator / Denominator Exclusion:</b> None</p> <p><b>Measure Description:</b> The percentage of diagnostic mammograms recommended for biopsy or surgical consult (BI-RADS® Category 4 or 5) that result in a tissue diagnosis of cancer within 12 months.</p>
Indication for examination	
Assessment category	
Biopsy date	
Classification of lesion	
Malignancy type	

### **Outcome Measure 2: Screening Mammography Positive Predictive Value 2**

Data Elements	Clinical Performance Measure
Indication for examination	<p><b>Numerator:</b> Number of screening mammograms with a BI-RADS® assessment category of 0, 4 or 5 that had a tissue diagnosis of cancer within 12 months.</p> <p><b>Denominator:</b> Number of screening mammograms with either a BI-RADS® assessment category of 4 or 5, or a BIRADS assessment category of 0 associated with category 4 or 5 on a diagnostic mammogram.</p> <p><b>Numerator / Denominator Exclusion:</b> None</p> <p><b>Measure Description:</b> The percentage of screening mammograms with abnormal interpretation (BI-RADS® category 0, 4 or 5) that result in a tissue diagnosis of cancer within 12 months.</p>
Assessment category	
Biopsy date	
Classification of lesion	
Malignancy type	

## NMD OUTCOME MEASURES

### Outcome Measure 3: Cancer Detection Rate

Data Elements	Clinical Performance Measure
Indication for examination Assessment category Biopsy date Classification of lesion Malignancy type	<b>Numerator:</b> Number of screening mammograms with a BI-RADS® assessment category of 0, 4 or 5 that had a tissue diagnosis of cancer within 12 months.  <b>Denominator:</b> Number of screening exams  <b>Numerator / Denominator Exclusion:</b> None  <b>Measure Description:</b> The percentage of screening mammograms that were interpreted as positive (BI-RADS® Category 0, 4 or 5) and result in a tissue diagnosis of cancer within 12 months.

### Outcome Measure 4: Abnormal interpretation rate of screening exams

Data Elements	Clinical Performance Measure
Indication for examination Assessment category	<b>Numerator:</b> Number of screening exams with a BI-RADS® assessment category of 0, 4 or 5.  <b>Denominator:</b> Number of screening exams  <b>Numerator / Denominator Exclusion:</b> None  <b>Measure Description:</b> The percentage of screening mammograms interpreted as positive (BI-RADS® Category 0, 4, or 5).